Key points of breast cancer management under public health emergencies

Since the end of February 2022, China has experienced a new wave of coronavirus disease 2019 (COVID-19) outbreaks caused by the Omicron variant. These outbreaks frequently occur at multiple sites, involving many provinces and cities. Prevention and control work is facing more challenges only after the Wuhan epidemic. As a general principle, the priority of treatment should be determined according to the biological features, clinical stages, and treatment stages of different breast cancer (BC) subtypes, and individualized diagnosis and treatment recommendations should be given. These patients belong to a high-priority population, for whom receiving treatment in a hospital is urgently required. In addition, treatment should also be prioritized for patients experiencing new tumor-related symptoms or serious adverse events. If the disease condition is stable, the frequency of follow-up re-examinations can be reduced according to the epidemic control situation. Online diagnosis and treatment are recommended to maintain doctor-patient communication. However, special attention should still be paid to treatment-associated safety issues, and safety monitoring measures should be adopted. For low-priority patients with stable disease, elective follow-up visits may be arranged after risk-benefit assessment based on the severity of the local COVID-19 epidemic and the risk of infection. Based on the above principle, we once again present our opinions on the top ten hot issues concerning the clinical diagnosis and treatment of BC during the COVID-19 epidemic in China.